More Prescription Drug Savings Are Coming In 2026:

​

There are a few other changes to prescription drug plans on the horizon. In 2024, Medicare negotiated for the first time the prices of 10 of the most commonly used and expensive prescription drugs. The lower prices take effect in 2026 and are expected to save people enrolled in Medicare an estimated $1.5 billion in out-of-pocket costs in 2026 alone.

The First 10 Drugs With Negotiated Prices Include:

• Eliquis (blood thinner)

• Jardiance (diabetes, heart failure, chronic kidney disease)

• Xarelto (blood thinner)

• Januvia (diabetes)

• Farxiga (diabetes, heart failure, chronic kidney disease)

• Entresto (heart failure)

• Enbrel (rheumatoid arthritis, psoriasis, psoriatic arthritis)

• Imbruvica (blood cancers)

• Stelara (psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis)

• NovoLog/Fiasp, several pens (diabetes)

In 2025, Medicare will select an additional 15 drugs covered under Part D to negotiate prices that will become available in 2027, and more medications will be negotiated each year beyond that.